Drugs / Glisodin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03941808 | Jun 2019 → May 2020 | vitiligo | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT03878433 Comparator | Apr 2019 → Jan 2020 | hyperpigmentation of the skin | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLISODin | “Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.” NCT03878433 ↗ |
| Modality | Protein / enzyme biologic | “oral superoxide dismutase (GLISODin)” NCT03878433 ↗ |
| Route | Oral | “Oral Superoxide Dismutase (GLISODin)” NCT03878433 ↗ |